Aven Recognition of RNA G-Quadruplexes Regulates
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
GLUTATHIONE TRANSFERASE N STRUCTURE and GENE REGULATION
GLUTATHIONE TRANSFERASE n STRUCTURE AND GENE REGULATION By Chu-Lin Xia This report is in part-fulfillment of the requirements for the degree of doctor of philosophy in the University of London University College, University of London January 1992 ProQuest Number: 10609162 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609162 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ABSTRACT In the early stage of this research, amino acid residues that are essential for the activity of human pi class glutathione transferase (GST n) were identified using chemical modification with group-specific reagents. Protection from inactivation by substrates, substrate analogues and inhibitors was used as the criterion for active site specificity. The results suggested the apparent involvement of one cysteine (Cys), one lysine (Lys), one arginine (Arg), one histidine (His) or tyrosine (Tyr) or both, one aspartate (Asp) or glutamate (Glu) and tryptophan (Trp) residues in the glutathione binding site (G-site) of GSTtc. It was concluded that without the knowledge of the three-dimensional structure of GST 7i, further work in this area would not be profitable and therefore, attention was turned to the regulation of GST n gene expression. -
BTG2: a Rising Star of Tumor Suppressors (Review)
INTERNATIONAL JOURNAL OF ONCOLOGY 46: 459-464, 2015 BTG2: A rising star of tumor suppressors (Review) BIjING MAO1, ZHIMIN ZHANG1,2 and GE WANG1 1Cancer Center, Institute of Surgical Research, Daping Hospital, Third Military Medical University, Chongqing 400042; 2Department of Oncology, Wuhan General Hospital of Guangzhou Command, People's Liberation Army, Wuhan, Hubei 430070, P.R. China Received September 22, 2014; Accepted November 3, 2014 DOI: 10.3892/ijo.2014.2765 Abstract. B-cell translocation gene 2 (BTG2), the first 1. Discovery of BTG2 in TOB/BTG gene family gene identified in the BTG/TOB gene family, is involved in many biological activities in cancer cells acting as a tumor The TOB/BTG genes belong to the anti-proliferative gene suppressor. The BTG2 expression is downregulated in many family that includes six different genes in vertebrates: TOB1, human cancers. It is an instantaneous early response gene and TOB2, BTG1 BTG2/TIS21/PC3, BTG3 and BTG4 (Fig. 1). plays important roles in cell differentiation, proliferation, DNA The conserved domain of BTG N-terminal contains two damage repair, and apoptosis in cancer cells. Moreover, BTG2 regions, named box A and box B, which show a high level of is regulated by many factors involving different signal path- homology to the other domains (1-5). Box A has a major effect ways. However, the regulatory mechanism of BTG2 is largely on cell proliferation, while box B plays a role in combination unknown. Recently, the relationship between microRNAs and with many target molecules. Compared with other family BTG2 has attracted much attention. MicroRNA-21 (miR-21) members, BTG1 and BTG2 have an additional region named has been found to regulate BTG2 gene during carcinogenesis. -
Colon Cancer and Protein Arginine Methyltransferase 1 Gene Expression
ANTICANCER RESEARCH 29: 1361-1366 (2009) Colon Cancer and Protein Arginine Methyltransferase 1 Gene Expression ALEXANDRA PAPADOKOSTOPOULOU1*, KONSTANTINA MATHIOUDAKI2*, ANDREAS SCORILAS3, DIMITRIOS XYNOPOULOS1, ALEXANDROS ARDAVANIS4, ELIAS KOUROUMALIS5 and MAROULIO TALIERI2 Departments of 1Gastroenterology and 2Cellular Physiology, G. Papanicolaou Research Center of Oncology, and 4Oncology, St. Savvas Hospital, Athens; 3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens; 5Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece Abstract. Background: In this study, the possible relation synthesis. Some of these modifications are reversible, such of the expression pattern of arginine methyltransferase 1 and as protein phosphorylation reactions, whereas others are colon cancer progression is investigated. Materials and apparently irreversible and can effectively create new types Methods: Colon cancer samples as well as normal colon of amino acids to broaden the chemical diversity of samples were used to define the arginine methyltransferase polypeptides. In this latter group of modifications, a 1 expression by RT-PCR. The results were associated with number of methylation reactions is included (1). Protein clinical and histological parameters of the tissues. Results: methylation involves transfer of a methyl group from S- In colon cancer tissue, only PRMT1 variants v1 and v2 were adenosylmethionine to acceptor groups on substrate often expressed. Statistical significance for the -
PRMT1, Human Recombinant Protein (Active) HMT2, HRMT1L2, IR1B4 Catalog # Pbv10454r
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PRMT1, human recombinant protein (Active) HMT2, HRMT1L2, IR1B4 Catalog # PBV10454r Specification PRMT1, human recombinant protein PRMT1, human recombinant protein (Active) - (Active) - Background Product info PRMT1 methylate’s (mono & asymmetric Primary Accession Q99873 dimethylation) the guanidino nitrogens of Calculated MW 84.0 kDa KDa arginyl residues present in a glycine and arginine-rich domain (may methylate HNRNPA1 and histones) methylate’s SUPT5H. The PRMT1 PRMT1, human recombinant protein (Active) - Additional Info protein functions as a histone methyltransferase specific for H4. PRMT1 is an essential factor in oncogenesis and is a Gene ID 3276 potential novel therapeutic target in cancer. Gene Symbol ANM1 PRMT1-mediated methylation serves as a Other Names positive modulator of IR/IRS-1/PI3K pathway Protein arginine N-methyltransferase 1, and glucose uptake in skeletal muscle cells. Histone-arginine N-methyltransferase CAF1 is a new regulator of PRMT1-dependent PRMT1, Interferon receptor 1-bound protein 4, Histone-arginine N-methyltransferase arginine methylation. PRMT1 PRMT1, Interferon receptor 1-bound protein arginine-methylate’s MRE11 therefore it 4 regulates the activity of MRE11-RAD50-NBS1 complex during the intra-S-phase DNA damage Gene Source Human checkpoint response. PRMT1 plays a Source E. coli post-translationally part in regulating the Assay&Purity SDS-PAGE; ≥90% transcriptional activity. PRMT1 is found predominantly in the cytoplasm, though a Assay2&Purity2 HPLC; fraction of PRMT1 is located in the nucleus. Recombinant Yes PRMT1 Human Recombinant (a.a. 1-353) fused Sequence MHHHHHHMKI with His-MBP tag at N-terminus produced in EEGKLVIWIN E.Coli is a single, non-glycosylated, polypeptide GDKGYNGLAE chain containing 750 amino acids and having a VGKKFEKDTG molecular mass of 84 kDa. -
2020 Program Book
PROGRAM BOOK Note that TAGC was cancelled and held online with a different schedule and program. This document serves as a record of the original program designed for the in-person meeting. April 22–26, 2020 Gaylord National Resort & Convention Center Metro Washington, DC TABLE OF CONTENTS About the GSA ........................................................................................................................................................ 3 Conference Organizers ...........................................................................................................................................4 General Information ...............................................................................................................................................7 Mobile App ....................................................................................................................................................7 Registration, Badges, and Pre-ordered T-shirts .............................................................................................7 Oral Presenters: Speaker Ready Room - Camellia 4.......................................................................................7 Poster Sessions and Exhibits - Prince George’s Exhibition Hall ......................................................................7 GSA Central - Booth 520 ................................................................................................................................8 Internet Access ..............................................................................................................................................8 -
Arginine Methylation Facilitates the Recruitment of TOP3B to Chromatin to Prevent R Loop Accumulation
Molecular Cell Article Arginine Methylation Facilitates the Recruitment of TOP3B to Chromatin to Prevent R Loop Accumulation Yanzhong Yang,1 Kevin M. McBride,1 Sean Hensley,1 Yue Lu,1 Frederic Chedin,2 and Mark T. Bedford1,* 1The University of Texas MD Anderson Cancer Center, P.O. Box 389, Smithville, TX 78957, USA 2Department of Molecular & Cellular Biology, The University of California at Davis, Davis, CA 95616, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.molcel.2014.01.011 SUMMARY nine methyltransferase 1), which deposit the H4R3me2a and H3R17me2a marks, respectively (Yang and Bedford, 2013). Tudor domain-containing protein 3 (TDRD3) is a Both of these marks are recognized by the Tudor domain of major methylarginine effector molecule that reads TDRD3 (Yang et al., 2010), a protein that is enriched at the pro- methyl-histone marks and facilitates gene transcrip- moters of highly transcribed genes and can likely also associate tion. However, the underlying mechanism by which with the C-terminal domain (CTD) of RNA Polymerase II (RNAP II) TDRD3 functions as a transcriptional coactivator is (Sims et al., 2011). TDRD3 has no enzymatic activity of its unknown. We identified topoisomerase IIIB (TOP3B) own, but here we show that it is tightly complexed with DNA topoisomerase IIIb (TOP3B), an interaction that bestows, in as a component of the TDRD3 complex. TDRD3 part, coactivator activity on TDRD3. TOP3B is a member of serves as a molecular bridge between TOP3B and the 1A subfamily of DNA topoisomerases and, as such, targets arginine-methylated histones. The TDRD3-TOP3B underwound or negatively supercoiled DNA (Wang, 2002). -
United States Patent (19) 11 Patent Number: 5,869,438 Svendsen Et Al
USOO5869438A United States Patent (19) 11 Patent Number: 5,869,438 Svendsen et al. (45) Date of Patent: Feb. 9, 1999 54) LIPASE WARIANTS 52 U.S. Cl. ......................... 510/226; 435/198; 435/69.1; 435/252.3; 435/320.1; 435/196; 536/23.2; 75 Inventors: Allan Svendsen, Birkerød; Shamkant 536/23.7; 530/350; 510/392; 510/305 Anant Patkar, Lyngby; Erik Gormsen, 58 Field of Search ..................................... 435/198, 196, Virum; Jens Sigurd Okkels; Marianne 435/187-188, 69.1, 252.3, 320.1, 71.1; Thellersen, both of Frederiksberg, all of 424/94.1; 536/22.2, 23.7; 510/305, 226, Denmark 392 73 Assignee: Novo Nordisk A/S, Bagsvaerd, 56) References Cited Denmark FOREIGN PATENT DOCUMENTS 21 Appl. No.: 479,275 O305 216 A1 3/1989 European Pat. Off.. O 407 225A1 1/1991 European Pat. Off.. 22 Filed: Jun. 7, 1995 WO95/09909 4/1995 WIPO. Related U.S. Application Data Primary Examiner Robert A. Wax ASSistant Examiner Tekchand Saidha 63 Continuation-in-part of PCT/DK94/00162, Apr. 22, 1994, which is a continuation-in-part of PCT/DK95/00079, Feb. Attorney, Agent, or Firm-Steve T. Belson; Elias J. 27, 1995, which is a continuation-in-part of Ser. No. 434, Lambiris 904, May 1, 1995, abandoned, which is a continuation of Ser. No. 977,429, which is a continuation of PCT/DK91/ 57 ABSTRACT 00271, Sep. 13, 1991, abandoned. The present invention relates to lipase variants which exhibit 30 Foreign Application Priority Data improved properties, detergent compositions comprising Said lipase variants, DNA constructs coding for Said lipase Sep. -
The Role of the Rho Gtpases in Neuronal Development
Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The role of the Rho GTPases in neuronal development Eve-Ellen Govek,1,2, Sarah E. Newey,1 and Linda Van Aelst1,2,3 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 11724, USA; 2Molecular and Cellular Biology Program, State University of New York at Stony Brook, Stony Brook, New York, 11794, USA Our brain serves as a center for cognitive function and and an inactive GDP-bound state. Their activity is de- neurons within the brain relay and store information termined by the ratio of GTP to GDP in the cell and can about our surroundings and experiences. Modulation of be influenced by a number of different regulatory mol- this complex neuronal circuitry allows us to process that ecules. Guanine nucleotide exchange factors (GEFs) ac- information and respond appropriately. Proper develop- tivate GTPases by enhancing the exchange of bound ment of neurons is therefore vital to the mental health of GDP for GTP (Schmidt and Hall 2002); GTPase activat- an individual, and perturbations in their signaling or ing proteins (GAPs) act as negative regulators of GTPases morphology are likely to result in cognitive impairment. by enhancing the intrinsic rate of GTP hydrolysis of a The development of a neuron requires a series of steps GTPase (Bernards 2003; Bernards and Settleman 2004); that begins with migration from its birth place and ini- and guanine nucleotide dissociation inhibitors (GDIs) tiation of process outgrowth, and ultimately leads to dif- prevent exchange of GDP for GTP and also inhibit the ferentiation and the formation of connections that allow intrinsic GTPase activity of GTP-bound GTPases (Zalc- it to communicate with appropriate targets. -
The PRMT1 Gene Expression Pattern in Colon Cancer
British Journal of Cancer (2008) 99, 2094 – 2099 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $32.00 www.bjcancer.com The PRMT1 gene expression pattern in colon cancer 1,5 2,5 3 2 4 ,1 K Mathioudaki , A Papadokostopoulou , A Scorilas , D Xynopoulos , N Agnanti and M Talieri* 1 Department of Cellular Physiology, ‘G Papanicolaou’ Research Center of Oncology, ‘Saint Savvas’ Hospital, 171 Alexandras Avenue, Athens 11522, Greece; 2Department of Gastroenterology, ‘Saint Savvas’ Hospital, 171 Alexandras Avenue, Athens 11522, Greece; 3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimioupoli, Athens 15711, Greece; 4Department of Pathology, School of Medicine, University of Ioannina, Ioannina 45110, Greece The methylation of arginine has been implicated in many cellular processes, such as regulation of transcription, mRNA splicing, RNA metabolism and transport. The enzymes responsible for this modification are the protein arginine methyltransferases. The most abundant methyltransferase in human cells is protein arginine methyltransferase 1. Methylation processes appear to interfere in the emergence of several diseases, including cancer. During our study, we examined the expression pattern of protein arginine methyltransferase 1 gene in colon cancer patients. The emerging results showed that the expression of one of the gene variants is associated with statistical significant probability to clinical and histological parameters, such as nodal status and stage. This is a first attempt to acquire an insight on the possible relation of the expression pattern of protein arginine methyltransferase 1 and colon cancer progression. British Journal of Cancer (2008) 99, 2094 – 2099. doi:10.1038/sj.bjc.6604807 www.bjcancer.com & 2008 Cancer Research UK Keywords: protein arginine methyltransferase; PRMT1; colon cancer; prognosis Colon cancer is one of the most dominant types of cancer in et al, 2005b; Cook et al, 2006) and can be classified into three Western industrialised countries. -
PRMT1-Dependent Regulation of RNA Metabolism and DNA Damage Response Sustains Pancreatic Ductal Adenocarcinoma ✉ Virginia Giuliani 1 , Meredith A
ARTICLE https://doi.org/10.1038/s41467-021-24798-y OPEN PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma ✉ Virginia Giuliani 1 , Meredith A. Miller1,17, Chiu-Yi Liu1,17, Stella R. Hartono 2,17, Caleb A. Class 3,13, Christopher A. Bristow1, Erika Suzuki1, Lionel A. Sanz2, Guang Gao1, Jason P. Gay1, Ningping Feng1, Johnathon L. Rose4, Hideo Tomihara4,14, Joseph R. Daniele1, Michael D. Peoples1, Jennifer P. Bardenhagen5, Mary K. Geck Do5, Qing E. Chang6, Bhavatarini Vangamudi1,15, Christopher Vellano1, Haoqiang Ying 7, Angela K. Deem1, Kim-Anh Do3, Giannicola Genovese4,8, Joseph R. Marszalek1, Jeffrey J. Kovacs1, Michael Kim9, 1234567890():,; Jason B. Fleming9,16, Ernesto Guccione10, Andrea Viale4, Anirban Maitra 11, M. Emilia Di Francesco5, Timothy A. Yap 12, Philip Jones 5, Giulio Draetta 1,4,5, Alessandro Carugo 1, Frederic Chedin 2 & ✉ Timothy P. Heffernan 1 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that has remained clini- cally challenging to manage. Here we employ an RNAi-based in vivo functional genomics platform to determine epigenetic vulnerabilities across a panel of patient-derived PDAC models. Through this, we identify protein arginine methyltransferase 1 (PRMT1) as a critical dependency required for PDAC maintenance. Genetic and pharmacological studies validate the role of PRMT1 in maintaining PDAC growth. Mechanistically, using proteomic and transcriptomic analyses, we demonstrate that global inhibition of asymmetric arginine methylation impairs RNA metabolism, which includes RNA splicing, alternative poly- adenylation, and transcription termination. This triggers a robust downregulation of multiple pathways involved in the DNA damage response, thereby promoting genomic instability and inhibiting tumor growth. -
ROLE of BRAIN SOLUBLE EPOXIDE HYDROLASE in CARDIOVASCULAR FUNCTION by KATHLEEN WALWORTH SELLERS a DISSERTATION PRESENTED TO
ROLE OF BRAIN SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR FUNCTION By KATHLEEN WALWORTH SELLERS A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2004 Copyright 2004 by Kathleen Walworth Sellers This work is dedicated to my family, who has taught me to embrace life with love, perseverance, and grace. ACKNOWLEDGMENTS I could not have completed this work without the assistance from many colleagues and friends. First and foremost, I would like to thank my mentor, Dr. Mohan Raizada, who has consistently supported and encouraged me these last several years. It was by chance that I worked in his research group before starting my graduate program, and I could not have found a better group with which to work. Dr. Raizada’s excitement and fervor for new ideas have helped shape my appreciation for scientific research and the pursuit of knowledge. I also want to acknowledge all of the members of the Raizada research group, past and present. I am fortunate to work in such a friendly and intellectually-stimulating environment. Specifically, I want to thank Drs. Beverly Falcon and Matthew Huentelman, the two graduate students in our research group who both helped me tremendously. In addition, I would like to thank Drs. Carlos Diez, Cheng-wen Sun, Jorge Vazquez, Shereeni Veerasingham and Hong Yang for all of their intellectual guidance. I greatly acknowledge the members of my committee, Drs. Michael Katovich, Gerard Shaw, Colin Sumners and Charles Wood. Each has provided me with unique experience and expertise to further my research and career. -
Rho Gtpases of the Rhobtb Subfamily and Tumorigenesis1
Acta Pharmacol Sin 2008 Mar; 29 (3): 285–295 Invited review Rho GTPases of the RhoBTB subfamily and tumorigenesis1 Jessica BERTHOLD2, Kristína SCHENKOVÁ2, Francisco RIVERO2,3,4 2Centers for Biochemistry and Molecular Medicine, University of Cologne, Cologne, Germany; 3The Hull York Medical School, University of Hull, Hull HU6 7RX, UK Key words Abstract Rho guanosine triphosphatase; RhoBTB; RhoBTB proteins constitute a subfamily of atypical members within the Rho fa- DBC2; cullin; neoplasm mily of small guanosine triphosphatases (GTPases). Their most salient feature 1This work was supported by grants from the is their domain architecture: a GTPase domain (in most cases, non-functional) Center for Molecular Medicine Cologne, the is followed by a proline-rich region, a tandem of 2 broad-complex, tramtrack, Deutsche Forschungsgemeinschaft, and the bric à brac (BTB) domains, and a conserved C-terminal region. In humans, Köln Fortune Program of the Medical Faculty, University of Cologne. the RhoBTB subfamily consists of 3 isoforms: RhoBTB1, RhoBTB2, and RhoBTB3. Orthologs are present in several other eukaryotes, such as Drosophi- 4 Correspondence to Dr Francisco RIVERO. la and Dictyostelium, but have been lost in plants and fungi. Interest in RhoBTB Phn 49-221-478-6987. Fax 49-221-478-6979. arose when RHOBTB2 was identified as the gene homozygously deleted in E-mail [email protected] breast cancer samples and was proposed as a candidate tumor suppressor gene, a property that has been extended to RHOBTB1. The functions of RhoBTB pro- Received 2007-11-17 Accepted 2007-12-16 teins have not been defined yet, but may be related to the roles of BTB domains in the recruitment of cullin3, a component of a family of ubiquitin ligases.